Diabetes Drug Developers Urged To Study Higher Risk Patients By FDA Panel

There is one message that sponsors should take to heart from an FDA advisory committee's first pass at applying new cardiovascular outcomes standards to type 2 diabetes medicines: enroll sicker patients in pivotal trials